Medicare told to reassess premium hike for Alzheimer's drug
January 10, 2022, 12:14 p.m. ·3 min read
WASHINGTON (AP) — U.S. health secretary Xavier Becerra on Monday ordered Medicare to reassess a big premium increase facing millions of enrollees this year, attributed in large part to a pricey new Alzheimer's drug with questionable benefits.
Becerra's directive came days after drugmaker Biogen slashed the price of its $56,000-a-year medication, Aduhelm, to $28,200 a year — a cut of about half.
"With the 50% price drop of Aduhelm on Jan. 1, there is a compelling basis ... to reexamine the previous recommendation," Becerra said in a statement about his directive to the Centers for Medicare and Medicaid Services.
More than 50 million Medicare recipients who pay the $170.10 monthly "Part B" premium for outpatient care will see no immediate change to their costs, but Monday's move could open the way for a reduction later in the year. The Department of Health and Human Services says it is reaching out to the Social Security Administration, which collects the premium, to examine options.
Medicare's standard premium is rising by about $22 this year, up from $148.50 in 2021 and one of the biggest annual increases ever. About half of that, $11, was attributed to the potential costs of having to cover Aduhelm at its original $56,000 price. Since Aduhelm is administered by infusion in a doctor's office the cost is factored into Medicare's outpatient coverage, not the separate prescription plan that pays for pharmacy medicines.
Becerra's move came after prominent Democratic senators urged the Biden administration to take immediate steps to cut rising drug costs for seniors. Much bigger curbs on drug prices promised by Democrats are hung up in Congress along with the rest of President Joe Biden's massive social agenda legislation. That bill would cap at $2,000 a year the amount Medicare recipients have to pay out-of-pocket for medicines, require drugmakers to pay the government rebates if they hike prices faster than inflation, and authorize Medicare to negotiate prices for certain medications.
In announcing the price cut just days before the Christmas holidays, Biogen acknowledged the high cost had become a stumbling block to uptake for its medication.
"Too many patients are not being offered the choice of Aduhelm due to financial considerations and are thus progressing beyond the point of benefitting from the first treatment to address an underlying pathology of Alzheimer's disease," CEO Michel Vounatsos said at the time. "We recognize that this challenge must be addressed in a way that is perceived to be sustainable for the U.S. healthcare system."
Medicare is currently covering Aduhelm on a case-by-case basis. Later this week, the agency is expected to issue an initial coverage decision, but the process of finalizing it can take months. Medicare said Monday it is reviewing Becerra's request to determine next steps.
Usually the financial impact of high-cost drugs falls most directly on patients with serious diseases such as cancer, rheumatoid arthritis or multiple sclerosis. But with Aduhelm, the pain would be spread among Medicare recipients generally, not just Alzheimer's patients needing the drug.
That's turned the drug into a case study of how one pricey treatment can swing the needle on government spending and impact household budgets. People who don't have Alzheimer's would still be on the hook for the cost of Aduhelm, since it's big enough to affect their premiums.
Alzheimer's is a progressive neurological disease with no known cure, affecting about 6 million Americans. The vast majority are old enough to qualify for Medicare, which covers more than 60 million people, including those 65 and older, and disabled people under 65.
Aduhelm is the first Alzheimer's medication in nearly 20 years. It doesn't cure the life-sapping condition, but the Food and Drug Administration determined that its ability to reduce clumps of plaque in the brain is likely to slow dementia in its earlier stages. However, many experts say that benefit has not been clearly demonstrated.
Ricardo Alonso-zaldivar, The Associated Press
Poll suggests support for Bill 21 provision may have dropped in Quebec; 55% in favour
MONTREAL — A new poll suggests support may have slipped for a key element of Quebec's secularism law, known as Bill 21. A web panel survey carried out by Leger for the Association for Canadian Studies earlier this month found 55 per cent of Quebecers are in favour of banning religious symbols being worn by public school teachers. That appears to be a drop from the results of a previous Leger survey published in September that found 64 per cent of Quebecers were in favour of Bill 21, which applie
Residents in Moncton area still without power following winter storm
Nearly 700 customers are still without power Sunday afternoon in New Brunswick. The majority of the power outages are happening in the Moncton area in Riverview, where 692 customers were without power as 1:30 p.m., according to N.B. Power. The power in the region is expected to return around 4:30 p.m. Over 700 were also without power in Madawaska and Victoria counties earlier Sunday morning, which include the communities of Notre Dame De Lourdes, Siegas and Ste-Anne-Madawaska. That brought the t
Explore Calgary's historic sites with updated interactive map of the city
Locals and visitors to Calgary can now explore the city's historic sites through an updated interactive map. On Monday, the City of Calgary and Heritage Calgary launched the Inventory of Evaluated Historic Resources Map. This updated map combines two older resources: the Discover Historic Calgary map and the Heritage Inventory database of historic sites. "It really is a treasure trove of information, and we're continuing to add sites to the inventory," said Josh Traptow, CEO of Heritage Calgary.
Crashed medical helicopter's pilot leaves hospital
The pilot of a medical helicopter that crash-landed without loss of life next to a church in a residential area of suburban Philadelphia last week thanked his crew and first responders. Danial Moore spoke as he left a hospital Sunday. (Jan. 17)
WASHINGTON (AP) — Charles McGee, a Tuskegee Airman who flew 409 fighter combat missions over three wars and later helped to bring attention to the Black pilots who had battled racism at home to fight for freedom abroad, died Sunday. He was 102. McGee died in his sleep at his home in Bethesda, Maryland, said his son, Ron McGee. After the U.S. entry into World War II, McGee left the University of Illinois to join an experimental program for Black soldiers seeking to train as pilots after the Army
French far-left presidential hopeful woos voters with jobs
NANTES, France (AP) — Far-left French presidential candidate Jean-Luc Melenchon embraced migrants and Russia and derided campaign rivals Sunday as he sought to reinvigorate his flagging campaign for April's election with an unusual "immersive and olfactory" rally. Yes, olfactory: The campaign team diffused various smells into the exhibition hall in the western city of Nantes, surrounding participants with screens and speakers. While the videos were powerful, with ocean waves and starscapes trans